TPL vs. CPRX
TPL (Texas Pacific Land Corporation) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. TPL operates in Oil & Gas E&P (Energy), while CPRX operates in Biotechnology (Healthcare). Over the past 10 years, TPL returned 37.18%/yr vs 48.24%/yr for CPRX. At a 0.14 correlation, their price movements are largely independent.
Performance
TPL vs. CPRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TPL achieves a 42.00% return, which is significantly higher than CPRX's 34.02% return. Over the past 10 years, TPL has underperformed CPRX with an annualized return of 37.18%, while CPRX has yielded a comparatively higher 48.24% annualized return.
TPL
- 1D
- 9.69%
- 1M
- -5.88%
- YTD
- 42.00%
- 6M
- 33.76%
- 1Y
- 9.02%
- 3Y*
- 40.33%
- 5Y*
- 21.25%
- 10Y*
- 37.18%
CPRX
- 1D
- 0.03%
- 1M
- 8.09%
- YTD
- 34.02%
- 6M
- 35.41%
- 1Y
- 25.57%
- 3Y*
- 39.39%
- 5Y*
- 41.68%
- 10Y*
- 48.24%
TPL vs. CPRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
TPL Texas Pacific Land Corporation | 42.00% | -21.61% | 115.31% | -32.40% | 91.29% | 73.25% | -4.69% | 44.58% | 21.96% | 51.18% |
CPRX Catalyst Pharmaceuticals, Inc. | 34.02% | 11.84% | 24.15% | -9.62% | 174.74% | 102.69% | -10.93% | 95.31% | -50.90% | 272.38% |
Correlation
The correlation between TPL and CPRX is -0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.02 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Nov 9, 2006 | 0.14 |
The correlation between TPL and CPRX shifts across timeframes, from -0.02 (1 year) to 0.24 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
TPL:
$28.07B
CPRX:
$3.97B
TPL:
$7.30
CPRX:
$1.74
TPL:
55.75
CPRX:
17.98
TPL:
2.95
CPRX:
0.32
TPL:
33.46
CPRX:
6.67
TPL:
18.04
CPRX:
3.92
TPL:
$839.03M
CPRX:
$596.96M
TPL:
$625.27M
CPRX:
$378.23M
TPL:
$690.06M
CPRX:
$313.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TPL vs. CPRX — Risk / Return Rank
TPL
CPRX
TPL vs. CPRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Texas Pacific Land Corporation (TPL) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| TPL | CPRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.57 | ||
| Sortino ratioReturn per unit of downside risk | -0.65 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.16 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 0.29 | 0.94 | -0.66 |
| Martin ratioReturn relative to average drawdown | 0.55 | 1.71 | -1.16 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| TPL | CPRX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.19 | 0.76 | -0.57 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.46 | 0.88 | -0.41 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.79 | 0.80 | -0.01 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.56 | 0.09 | +0.47 |
Drawdowns
TPL vs. CPRX - Drawdown Comparison
The maximum TPL drawdown since its inception was -73.05%, smaller than the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for TPL and CPRX.
Loading charts...
Drawdown Indicators
| TPL | CPRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -73.05% | -94.25% | +21.20% |
Max Drawdown (1Y)Largest decline over 1 year | -31.68% | -27.29% | -4.39% |
Max Drawdown (3Y)Largest decline over 3 years | -52.22% | -27.29% | -24.93% |
Max Drawdown (5Y)Largest decline over 5 years | -52.50% | -45.37% | -7.13% |
Max Drawdown (10Y)Largest decline over 10 years | -65.46% | -64.87% | -0.59% |
Current DrawdownCurrent decline from peak | -28.77% | -0.16% | -28.61% |
Average DrawdownAverage peak-to-trough decline | -27.26% | -52.05% | +24.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.70% | 14.95% | +1.75% |
Volatility
TPL vs. CPRX - Volatility Comparison
Texas Pacific Land Corporation (TPL) has a higher volatility of 14.43% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 6.81%. This indicates that TPL's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TPL | CPRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.43% | 6.81% | +7.62% |
Volatility (6M)Calculated over the trailing 6-month period | 38.02% | 23.58% | +14.44% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.51% | 33.60% | +12.91% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 46.20% | 47.86% | -1.66% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 47.07% | 60.61% | -13.54% |
Dividends
TPL vs. CPRX - Dividend Comparison
TPL's dividend yield for the trailing twelve months is around 0.56%, while CPRX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CPRX Catalyst Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
TPL Texas Pacific Land Corporation | 0.56% | 0.74% | 1.37% | 0.83% | 1.37% | 0.88% | 2.20% | 0.22% | 0.55% | 0.30% | 0.10% | 0.22% |
Financials
TPL vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between Texas Pacific Land Corporation and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TPL vs. CPRX - Profitability Comparison
TPL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Texas Pacific Land Corporation reported a gross profit of 0.00 and revenue of 236.82M. Therefore, the gross margin over that period was 0.0%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.
TPL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Texas Pacific Land Corporation reported an operating income of 182.33M and revenue of 236.82M, resulting in an operating margin of 77.0%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.
TPL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Texas Pacific Land Corporation reported a net income of 142.90M and revenue of 236.82M, resulting in a net margin of 60.3%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.
Frequently Asked Questions
TPL and CPRX have a correlation of -0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TPL has higher volatility (14.43%) compared to CPRX (6.81%). In terms of maximum drawdown, TPL dropped -73.05% vs CPRX's -94.25%.
CPRX currently has the higher Sharpe Ratio (0.76 vs 0.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TPL and CPRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer